The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors
Immunity · 2025
DOI: 10.1016/j.immuni.2025.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2025. Verfasst von Joseph Léger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44007 Nantes, France. Hauptthemen laut MEDLINE: Immunity, Innate, Lymphoid Progenitor Cells, Basic-Leucine Zipper Transcription Factors, Lymphocytes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National League Against Cancer, Foundation for Medical Research.
Abstract (Originalsprache)
Understanding the mechanisms that initiate innate lymphoid cell (ILC) specification may reveal how ILC functions in immunity and tissue homeostasis are programmed. Using an Il7r-lineage tracing mouse strain, we identified developmental intermediates between lymphoid progenitors and Tcf7+ ILC progenitors in the mouse bone marrow (BM). Transcriptional analysis of these intermediates identified very early expression of the transcription factor nuclear factor, interleukin 3 regulated (NFIL3). Nfil3-/- mice lacked all BM ILC-specified precursors. Forced expression of NFIL3 in lymphoid progenitors induced Tcf7+ ILC-lineage cells capable of generating all ILC subsets and conventional natural killer cells. Transient activity of NFIL3 in lymphoid precursors recapitulated BM ILC development in vitro, leading to the generation of all adult ILCs. Mechanistically, NFIL3 initiated ILC specification by inducing expression of key transcriptional regulators of ILC development-Tox, Id2, Gata3, Tcf7, and Zbtb16. Our findings indicate an apex role for NFIL3 in ILC specification and provide an in vitro approach to generate ILC-lineage cells with potential therapeutic utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44007 Nantes, France.
- Laboratory of Genome Integrity, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Laboratory of Genome Integrity, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: avinash.bhandoola@nih.gov.
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44007 Nantes, France; Laboratory of Genome Integrity, Center for Cancer Research, National Cancer Institute, National Institutes of Health…
Förderung
- Intramural NIH HHS
- National League Against Cancer
- Foundation for Medical Research
- French National Research Agency
- National Centre for Scientific Research
- Institut National de la Santé et de la Recherche Médicale
- Université de Nantes
- National Cancer Institute
Zitieren
APA
Léger, J., Artano, E., Coulais, D., Belletoise, N., Fadhloun, R., Kenney, D., Bhandoola, A., & Harly, C. (2025). The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors. Immunity. https://doi.org/10.1016/j.immuni.2025.10.005
Vancouver
Léger J, Artano E, Coulais D, Belletoise N, Fadhloun R, Kenney D, et al. The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors. Immunity. 2025. doi:10.1016/j.immuni.2025.10.005
BibTeX
@article{Lger2025,
author = {Léger, Joseph and Artano, Eva and Coulais, Delphine and Belletoise, Naomie and Fadhloun, Raoudha and Kenney, Devin and Bhandoola, Avinash and Harly, Christelle},
title = {The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors},
journal = {Immunity},
year = {2025},
doi = {10.1016/j.immuni.2025.10.005}
}
EUVIMED